West China Second University Hospital

This study tests a new oral drug, luvometinib, in children aged 0-18 with Langerhans cell histiocytosis (LCH) affecting special bones like the skull base or spine. The drug targets overactive cell signals that drive the disease. Researchers want to see if it can control the disea…

This study is for children aged 0-18 with a severe form of Langerhans cell histiocytosis (LCH) that affects multiple organs. It compares standard chemotherapy alone to the same chemotherapy plus a targeted drug called luvometinib. The goal is to see if adding luvometinib helps mo…